Clinical Trial Update: Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 study of pevonedistat plus azacitidine, fludarabine phosphate, and cytarabine in relapsed or refractory acute myeloid leukemia or myelodysplastic syndro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Prior Myelodysplastic Syndrome
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Fludarabine phosphate (Fludarabine phosphate)
• Pevonedistat (pevonedistat)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2023-03-03